Hyderabad (Telangana) [India], June 17 (ANI): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press
Hyderabad (Telangana) [India], December 30 (ANI): Hyderabad based vaccine manufacturer Bharat Biotech on Thursday announced that Covaxin (BBV152) has been found to be "safe, well-tolerated, and immunogenic" in the age group of 2-18 years in phase II/III study, said a company's statement.
New Delhi [India], June 3 (ANI): A Fresh application was moved in Delhi High Court on Thursday seeking to stay the operation of the order of Drugs Controller General of India (DCGI) for conducting phase II/III clinical trials of Whole Virion Inactivated Coronavirus Vaccine in the 2 to 18 yea